News

The Phase IIb trial will compare the safety and efficacy of two dose levels of TB-402, given as a single intravenous infusion after hip surgery, with the recently

Durata has taken over the Japanese commercialization rights for dalbavancin from RaQualia Pharma in December 2010. All other rights, including in North America and the European Union, were

The milestone marks the completion of the Lerentang Pharmaceutical company’s manufacturing facility relocation from Shijiazhuang to Xinle City and Hebei Province. Aoxing Pharma has obtained $269,231 in the

The Phase 3 trial will investigate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1 HCV. The company will recruit around 1,875 patients

The joint venture is among the first initiatives in Gumlink’s nutraceutical strategy for the future involving strategic collaborations with various industry partners, as announced in January this year.

AstraZeneca is in talks with relevant authorities on a trade name and is currently referring to the treatment by its generic name, vandetanib. AstraZeneca Specialty Care vice president

The FDA has asked the company to submit its study protocols to the INDs for further discussions in order to provide review and feedback on the proposed studies.

DKSH’s Business Unit Performance Materials is a specialty chemicals distributor and a provider of Market Expansion Services for performance materials. The Business Unit sources, develops, markets and distributes

Reportedly, the FDA warned Tec Laboratories over its StaphAseptic First Aid Antiseptic/Pain Relieving Gel, which claims on the label to kill ‘over 99.9% of MRSA, staph and strep.’